Analysts’ Viewpoint
High prevalence of viral diseases and rise in awareness about infectious diseases and their treatment options among consumers are key factors driving the global market. Growth in government funding to enhance drug approvals is also boosting the anti-infective drugs market revenue. Furthermore, increase in R&D and technological advancements are augmenting the market.
Manufacturers are concentrating on new product launches, approvals, and collaborations to gain value-grab anti-infective drugs market opportunities. Anti-infective drug companies are focusing on expanding their production capacity post the peak of the COVID-19 pandemic. Government organizations such as the WHO and UNICEF are also increasing funding to enhance product approvals. However, side-effects associated with anti-infective drugs and shortage of resources in certain low- and middle-income countries (LMIC) are likely to restrain market growth in the near future.
Anti-infective drugs are medications used to treat or prevent infections caused by bacteria, viruses, fungi, or parasites. These drugs can work in various ways, such as by killing the infectious organism or by inhibiting its growth and replication.
Common examples of anti-infective drugs include antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are used to treat bacterial infections in patients, while antivirals are used to treat viral infections. Antifungals help treat fungal infections, whereas antiparasitics are used to treat parasitic infections.
Tuberculosis (TB) is the world’s second-largest infectious disease after COVID-19. In 2020, TB accounted for an estimated 1.5 million deaths (including people with HIV). After South Africa, India is the leading country with high prevalence of HIV/AIDS worldwide.
New infectious diseases such as avian flu and swine flu are also emerging at a higher rate and spreading more rapidly than ever in communities. Thus, the global demand for anti-infective drugs is expected to increase during the forecast period.
Growth in government initiatives to create awareness about infectious diseases and their treatment options is a key factor fueling the anti-infective drugs market expansion. Governments of several countries are increasingly investing in laboratory infrastructure and diagnostic capacities.
As per an article published by the Centers for Disease Control and Prevention (CDC), in September 2021, the Biden-Harris administration invested US$ 2.1 Bn to improve infection prevention and control activities across the U.S. public health and healthcare sector.
Rise in investment in R&D activities of anti-infective drugs due to surge in various new infectious diseases, such as COVID-19, is driving the global market. In 2019, the pharmaceutical sector invested US$ 83.0 Bn in R&D of anti-infective drugs.
The COVID-19 pandemic has had a significant impact on the global market for anti-infective drugs. Several industries, lives, communities, and businesses were negatively affected owing to the restrictions imposed by various countries during the pandemic. Anti-infective drugs helped prevent the spread of the SARS-CoV-2 virus.
Besides the increase in R&D spending in the private sector, the federal government has provided support to the private sector to develop vaccines in order to address the pandemic. In June 2022, the Frontiers in Immunology recommended the usage of antimicrobial peptides and antibodies as anti-infective agents against the SARS-CoV-2 virus. Wide use of anti-infective drugs to arrest the spread of COVID-19 among the population significantly contributed to anti-infective drugs market growth.
In terms of drug class, the global anti-infective drugs market has been segmented into antibacterials, antivirals, antifungals, and others. The antivirals drug class segment is anticipated to dominate the global market during the forecast period, owing to the rise in prevalence of new infectious diseases.
Several market players and government organizations have been focusing on production and manufacture of antiviral drugs. In January 2022, the UNICEF signed several LTA (long-term agreements) with suppliers for the procurement of Molnupiravir, a new antiviral medicine.
In October 2021, Merck & Co., Inc. signed a voluntary licensing agreement with Medicines Patent Pool (MPP), a United Nations-backed public health organization. The agreement facilitates affordable global access to Molnupiravir, which is an investigational oral COVID-19 antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults. These initiatives are likely to boost the antiviral drugs segment growth during the forecast period.
According to the latest anti-infective drugs market forecast, the retail pharmacies distribution channel segment is anticipated to lead the global industry during the forecast period.
Retail pharmacies sell over-the-counter drugs such as common cold medicines, antipyretics, and analgesics. The number of retail pharmacies is increasing rapidly across the globe. Thus, presence of large number of knowledgeable pharmacists who review prescriptions for infectious diseases is contributing to the segment growth.
North America accounted for the largest share of the global market in 2022. The region is anticipated to lead the global landscape in the next few years, owing to the improved healthcare infrastructure and presence of well-established distribution channels in the U.S. and Canada.
Growth in the pharmaceutical sector and favorable reimbursement policies are key factors boosting market statistics in North America. Antivirals are recommended for the treatment of several infectious disorders by the Centers for Disease Control and Prevention (CDC) in the U.S. Rise in government efforts to promote the usage of antivirals is also augmenting market progress in the region.
The anti-infective drugs market size in Asia Pacific is projected to increase at a rapid pace, owing to the presence of large number of generic companies, rise in economic stability, and increase in disposable income of consumers in the region. Furthermore, surge in geriatric population that is prone to infections is projected to fuel anti-infective drugs market growth in Asia Pacific in the near future.
The global landscape is consolidated, with the presence of several key players that control majority of the market share. According to the anti-infective drugs market research, leading companies are focusing on mergers & acquisitions, new product development, and product portfolio expansion to gain incremental opportunities.
Pfizer Inc., Gland Pharma Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Abbott, Astellas Pharma Inc., Alkem Laboratories, AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, and Sanofi are key players operating in the global market. These players are following the anti-infective drugs market trends to avail lucrative revenue opportunities.
Prominent players have been profiled in the anti-infective drugs market report based on parameters such as financial overview, product portfolio, latest developments, business strategies, business segments, and company overview.
| Attribute | Details |
|---|---|
|
Market Value in 2022 |
US$ 139.1 Bn |
|
Market Forecast Value in 2031 |
More than US$ 177.9 Bn |
|
Growth Rate (CAGR) |
4.0% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 139.1 Bn in 2022
It is projected to reach more than US$ 177.9 Bn by 2031
The CAGR is anticipated to be 4.0% from 2023 to 2031
Increase in prevalence of viral diseases and rise in government funding and initiatives to enhance drug approvals
The antiviral drug class segment accounted for major share in 2022
North America is likely to account for major share from 2023 to 2031
Pfizer Inc., Gland Pharma Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Abbott, Astellas Pharma Inc., Alkem Laboratories, AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, and Sanofi
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anti-infective Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anti-infective Drugs Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate Globally With Key Countries
5.2. Regulatory Scenario, by Region
5.3. Reimbursement Scenario by Region/Globally
5.4. Pipeline Analysis
5.5. Key Product/Brand Analysis
5.6. Key Mergers & Acquisitions
5.7. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Anti-infective Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Antibacterials
6.3.1.1. B-lactams
6.3.1.2. Quinolones
6.3.1.3. Macrolides
6.3.1.4. Tetracycline
6.3.1.5. Aminoglycoside
6.3.1.6. Others
6.3.2. Antivirals
6.3.2.1. Miscellaneous Antivirals
6.3.2.2. Adamantane Antivirals
6.3.2.3. Antiviral Boosters
6.3.2.4. Others
6.3.3. Antifungals
6.3.3.1. Azoles
6.3.3.2. Echinocandins
6.3.3.3. Polyenes
6.3.3.4. Others
6.3.4. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Anti-infective Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Others
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Anti-infective Drugs Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2017-2031
8.3.1. Pneumonia
8.3.2. Sepsis
8.3.3. Tuberculosis
8.3.4. Influenza
8.3.5. HIV Infection
8.3.6. Hepatitis Virus Infection
8.3.7. Respiratory Virus Infection
8.3.8. Others
8.4. Market Attractiveness Analysis, by Indication
9. Global Anti-infective Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Anti-infective Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Anti-infective Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Antibacterials
11.2.1.1. B-lactams
11.2.1.2. Quinolones
11.2.1.3. Macrolides
11.2.1.4. Tetracycline
11.2.1.5. Aminoglycoside
11.2.1.6. Others
11.2.2. Antivirals
11.2.2.1. Miscellaneous Antivirals
11.2.2.2. Adamantane Antivirals
11.2.2.3. Antiviral Boosters
11.2.2.4. Others
11.2.3. Antifungals
11.2.3.1. Azoles
11.2.3.2. Echinocandins
11.2.3.3. Polyenes
11.2.3.4. Others
11.2.4. Others
11.3. Market Value Forecast, by Route of Administration, 2017-2031
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Others
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Pneumonia
11.4.2. Sepsis
11.4.3. Tuberculosis
11.4.4. Influenza
11.4.5. HIV Infection
11.4.6. Hepatitis Virus Infection
11.4.7. Respiratory Virus Infection
11.4.8. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe Anti-infective Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Antibacterials
12.2.1.1. B-lactams
12.2.1.2. Quinolones
12.2.1.3. Macrolides
12.2.1.4. Tetracycline
12.2.1.5. Aminoglycoside
12.2.1.6. Others
12.2.2. Antivirals
12.2.2.1. Miscellaneous Antivirals
12.2.2.2. Adamantane Antivirals
12.2.2.3. Antiviral Boosters
12.2.2.4. Others
12.2.3. Antifungals
12.2.3.1. Azoles
12.2.3.2. Echinocandins
12.2.3.3. Polyenes
12.2.3.4. Others
12.2.4. Others
12.3. Market Value Forecast, by Route of Administration, 2017-2031
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Others
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Pneumonia
12.4.2. Sepsis
12.4.3. Tuberculosis
12.4.4. Influenza
12.4.5. HIV Infection
12.4.6. Hepatitis Virus Infection
12.4.7. Respiratory Virus Infection
12.4.8. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Anti-infective Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Antibacterials
13.2.1.1. B-lactams
13.2.1.2. Quinolones
13.2.1.3. Macrolides
13.2.1.4. Tetracycline
13.2.1.5. Aminoglycoside
13.2.1.6. Others
13.2.2. Antivirals
13.2.2.1. Miscellaneous Antivirals
13.2.2.2. Adamantane Antivirals
13.2.2.3. Antiviral Boosters
13.2.2.4. Others
13.2.3. Antifungals
13.2.3.1. Azoles
13.2.3.2. Echinocandins
13.2.3.3. Polyenes
13.2.3.4. Others
13.2.4. Others
13.3. Market Value Forecast, by Route of Administration, 2017-2031
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Others
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1. Pneumonia
13.4.2. Sepsis
13.4.3. Tuberculosis
13.4.4. Influenza
13.4.5. HIV Infection
13.4.6. Hepatitis Virus Infection
13.4.7. Respiratory Virus Infection
13.4.8. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Anti-infective Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Antibacterials
14.2.1.1. B-lactams
14.2.1.2. Quinolones
14.2.1.3. Macrolides
14.2.1.4. Tetracycline
14.2.1.5. Aminoglycoside
14.2.1.6. Others
14.2.2. Antivirals
14.2.2.1. Miscellaneous Antivirals
14.2.2.2. Adamantane Antivirals
14.2.2.3. Antiviral Boosters
14.2.2.4. Others
14.2.3. Antifungals
14.2.3.1. Azoles
14.2.3.2. Echinocandins
14.2.3.3. Polyenes
14.2.3.4. Others
14.2.4. Others
14.3. Market Value Forecast, by Route of Administration, 2017-2031
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Others
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Pneumonia
14.4.2. Sepsis
14.4.3. Tuberculosis
14.4.4. Influenza
14.4.5. HIV Infection
14.4.6. Hepatitis Virus Infection
14.4.7. Respiratory Virus Infection
14.4.8. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Anti-infective Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017-2031
15.2.1. Antibacterials
15.2.1.1. B-lactams
15.2.1.2. Quinolones
15.2.1.3. Macrolides
15.2.1.4. Tetracycline
15.2.1.5. Aminoglycoside
15.2.1.6. Others
15.2.2. Antivirals
15.2.2.1. Miscellaneous Antivirals
15.2.2.2. Adamantane Antivirals
15.2.2.3. Antiviral Boosters
15.2.2.4. Others
15.2.3. Antifungals
15.2.3.1. Azoles
15.2.3.2. Echinocandins
15.2.3.3. Polyenes
15.2.3.4. Others
15.2.4. Others
15.3. Market Value Forecast, by Route of Administration, 2017-2031
15.3.1. Oral
15.3.2. Parenteral
15.3.3. Others
15.4. Market Value Forecast, by Indication, 2017-2031
15.4.1. Pneumonia
15.4.2. Sepsis
15.4.3. Tuberculosis
15.4.4. Influenza
15.4.5. HIV Infection
15.4.6. Hepatitis Virus Infection
15.4.7. Respiratory Virus Infection
15.4.8. Others
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Route of Administration
15.7.3. By Indication
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by Tier and Size of Companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Pfizer Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Gland Pharma Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. F. Hoffmann-La Roche Ltd.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Novartis AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. GlaxoSmithKline plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Gilead Sciences, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Merck & Co., Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Abbott
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Astellas Pharma Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Alkem Laboratories
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. AstraZeneca
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Eli Lilly and Company
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Johnson & Johnson Services, Inc.
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Takeda Pharmaceutical Company Limited
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Product Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview
16.3.16. Sanofi
16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.16.2. Product Portfolio
16.3.16.3. Financial Overview
16.3.16.4. SWOT Analysis
16.3.16.5. Strategic Overview
List of Tables
Table 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 02: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 03: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 04: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 05: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 06: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 07: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 08: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 09: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 10: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 11: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 12: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 13: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 14: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 15: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 17: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 18: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 19: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 20: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 21: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 22: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 23: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 25: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 26: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 27: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 28: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 29: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 30: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 31: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 32: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 33: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 34: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 35: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 36: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 37: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 38: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 39: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 40: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 41: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 42: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 43: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 44: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 45: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 46: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 47: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 48: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
Figure 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 03: Global Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 04: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antibacterials, 2017-2031
Figure 05: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antivirals, 2017-2031
Figure 06: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antifungals, 2017-2031
Figure 07: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 08: Global Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 09: Global Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 10: Global Anti-infective Drugs Market Revenue (US$ Mn), by Oral, 2017-2031
Figure 11: Global Anti-infective Drugs Market Revenue (US$ Mn), by Parenteral, 2017-2031
Figure 12: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 13: Global Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
Figure 14: Global Anti-infective Drugs Market Revenue (US$ Mn), by Pneumonia, 2017-2031
Figure 15: Global Anti-infective Drugs Market Revenue (US$ Mn), by Sepsis, 2017-2031
Figure 16: Global Anti-infective Drugs Market Revenue (US$ Mn), by Tuberculosis, 2017-2031
Figure 17: Global Anti-infective Drugs Market Revenue (US$ Mn), by Influenza, 2017-2031
Figure 18: Global Anti-infective Drugs Market Revenue (US$ Mn), by HIV Infection, 2017-2031
Figure 19: Global Anti-infective Drugs Market Revenue (US$ Mn), by Hepatitis Virus Infection, 2017-2031
Figure 20: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 21: Global Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 22: Global Anti-infective Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 23: Global Anti-infective Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 24: Global Anti-infective Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
Figure 25: Global Anti-infective Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 26: Global Anti-infective Drugs Market Attractiveness Analysis, by Region, 2022-2031
Figure 27: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 28: North America Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 29: North America Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 30: North America Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 31: North America Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 32: North America Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 33: North America Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
Figure 34: North America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 35: North America Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 36: North America Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 37: North America Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
Figure 38: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 39: Europe Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 40: Europe Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 41: Europe Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 42: Europe Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 43: Europe Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 44: Europe Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
Figure 45: Europe Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 46: Europe Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 47: Europe Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 48: Europe Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
Figure 49: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 50: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 51: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 52: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 53: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 54: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 55: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
Figure 56: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 57: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 58: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 59: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
Figure 60: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 61: Latin America Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 62: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 63: Latin America Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 64: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 65: Latin America Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 66: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
Figure 67: Latin America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 68: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 69: Latin America Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 70: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
Figure 71: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 72: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 73: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 74: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 75: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 76: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 77: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
Figure 78: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 79: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 80: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 81: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
Figure 82: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Anti-Infective Drugs Market
*86 figures and 60 tables includes